Ocular surface disease (OSD)—including dry eye disease, blepharitis, meibomian gland dysfunction, conjunctival inflammation, and cicatrizing ocular surface disorders—is one of the most common and underrecognized factors affecting the success of eye surgery (e.g., refractive, cataract, glaucoma, strabismus, retina, and oculoplastic). Conversely, optimizing the ocular surface is one of the most effective, modifiable strategies for enhancing surgical success across all ophthalmic subspecialties. And the central clinical principle appears to be universal: elective eye surgery...
TFOS is pleased to announce a new strategic partnership with EssilorLuxottica, a global leader in vision care and eyewear. This collaboration will support shared efforts to elevate awareness, education, and scientific progress in tear film and ocular surface health worldwide. By combining TFOS’s expertise in evidence-based consensus and professional education with EssilorLuxottica’s global reach and innovation capabilities, the partnership aims to help improve standards of care for patients affected by dry eye disease and related ocular surface conditions. Together, TFOS and EssilorLuxottica...
TFOS has organized a special meeting of the Latin American TFOS Ambassadors. This meeting, which will occur in Panama City this May, has two goals: first, to address the unmet needs for the management (e.g. diagnosis & treatment) of ocular surface diseases in their country/region, as well as what the Ambassadors perceive as short and long term scientific/clinical solutions; and second, to create a report for publication in a peer-reviewed journal. Participants will include TFOS Ambassadors from Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras,...
